The future of checkpoint inhibition in multiple myeloma?

Lancet Haematol. 2019 Sep;6(9):e439-e440. doi: 10.1016/S2352-3026(19)30149-8. Epub 2019 Jul 18.

Author

Caitlin Costello¹

Affiliation

¹ Department of Medicine, Division of Blood and Marrow Transplant, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: ccostello@ucsd.edu.

PMID: 31327688
DOI: 10.1016/S2352-3026(19)30149-8

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Dexamethasone
Humans
Lenalidomide
Multiple Myeloma*

Substances

Antibodies, Monoclonal, Humanized
Dexamethasone
pembrolizumab
Lenalidomide